

RESEARCH LETTER

Open Access



Detection of IgG antibody during the follow-up in patients with COVID-19 infection

Jiao Liu^{1,2†}, Jun Guo^{3†}, Qianghong Xu^{4†}, Guolong Cai^{4†}, Dechang Chen^{1,2*} and Yanfei Shen^{4*} 

Although most patients with COVID-19 in China have been cured and discharged, we noticed a small proportion of these patients had re-positive RT-PCR test during the follow-up period [1]. The causes of this re-infection remain unclear. In common COVID-19 cases [2], both the IgM and IgG antibodies significantly increased within a short period. However, in a case series report [3], the IgG was relatively low in re-infected COVID-19 cases. Thus, we investigated the IgG status in recovered patients during the follow-up period.

This retrospective study was performed in Wuhan JiangBei Hospital, China. COVID-19 infection was confirmed by the RT-PCR test. The IgM and IgG antibodies were detected using colloidal immunization methods. Only cured patients were included in this analysis. Patient consent was waived due to the retrospective nature. The ethics committee of Wuhan JiangBei Hospital approved this study.

During follow-up, only simple tests were performed, such as blood routine examination, antibody test, and chest computed tomography (CT). For accuracy, missing data were not imputed.

Continuous variables were presented as mean \pm standard deviation, and Student's *t* test was used unless indicated. Categorical data were compared using the chi-square test. $p < 0.05$ was considered statistically

significant. All statistical analyses were performed using STATA 14.0.

We studied 484 patients with positive IgG, the minimum period from onset to IgG detection was 10 days, and the maximum period was 100 days (Fig. 1). Meanwhile, 18% of these patients had negative IgG results, and this was confirmed by more than two IgG tests in 37 patients. The mean duration from onset to IgG test was close between positive and negative IgG groups (50.5 ± 14.8 vs. 43.3 ± 15.0 , days).

Further, compared to the negative IgG group, both the lymphocyte (1.3 ± 0.0 vs. 1.6 ± 0.1 , $p = 0.001$) and neutrophil counts (3.5 ± 1.6 vs. 5.0 ± 3.0 , $p < 0.001$) were lower in the positive group. Besides, the percent of abnormal CT findings at follow-up was higher in the positive IgG group (259/372 vs. 22/64, $p < 0.001$) (Table 1).

Re-infection with COVID-19 in recovered patients has been occasionally encountered in clinical practice. Weak evidence [3] indicated that the IgG level was low in these re-infected COVID-19 cases. As IgG plays a critical role in immune response, understanding IgG status in recovered patients is necessary for preventing re-infections. In the current study, we found that 18% of the recovered patients had negative IgG. The mechanism remains unclear. However, we also found that compared to the positive group, the lymphocyte on hospital admission was higher in the negative group. Evidence [4, 5] has indicated that lymphocyte count is an independent predictor for COVID-19 severity. Thus, we inferred that compared to patients with positive IgG, those with negative IgG might have relatively mild COVID-19 infection, and the slight impact on their immune system leads to

* Correspondence: cdcshjt@126.com; snow.shen@hotmail.com

[†]Jiao Liu, Jun Guo, Qianghong Xu, and Guolong Cai are listed as co-first authors.

¹Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai, China

⁴Department of Critical Care Medicine, Zhejiang Hospital, No. 12, Linyin Road, Hangzhou 310000, Zhejiang, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Table 1 Comparisons between patients with positive and negative IgG antibody

Variables	Positive IgG (n = 397)	Negative IgG (n = 87)	Negative IgG (≥ 2 tests) (n = 37)	p
Age (years)	51.2 ± 13.9	49.6 ± 17.2	51.8 ± 19.4	0.365
Gender (male, %)	190 (47.8)	43 (49.4)	13 (35.1)	0.791
White blood cell count on admission	5.3 ± 1.8	7.1 ± 3.1	6.9 ± 2.7	< 0.001
Lymphocyte count on admission	1.3 ± 0.0	1.6 ± 0.1	1.6 ± 0.7	0.001
Neutrophil count on admission	3.5 ± 1.6	5.0 ± 3.0	4.7 ± 2.5	< 0.001
White blood cell count at follow-up	6.3 ± 1.7	6.5 ± 1.8	6.2 ± 1.8	0.387
Lymphocyte count at follow-up	2.1 ± 0.6	2.1 ± 0.6	2.0 ± 0.7	0.738
Neutrophil count at follow-up	3.7 ± 1.4	3.9 ± 1.4	3.6 ± 1.3	0.296
Maximum duration of IgG test	50.5 ± 14.8	43.3 ± 15.0	50.6 ± 12.1	< 0.001
Maximum duration of IgG test*, median (min and max value)	51 (10–100)	42 (2–90)	50 (28–90)	< 0.001
Abnormal CT findings at follow-up# (which indicate residual infection)	259/372	22/64	10/32	< 0.001

All comparisons were made between positive IgG and negative IgG groups
 IgG immunoglobulin G, CT computed tomography
 *Presented as median (minimum and maximum value), compared using rank-sum test
 #Any chest CT findings that suggested residual infection during follow-up were defined as abnormal

the higher lymphocyte and negative IgG during the follow-up period. This hypothesis was also supported by the CT finding that the residual infection on chest CT disappears more quickly in patients with negative IgG. If this is the case, the risk of re-infection of COVID-19 in these patients should be carefully assessed in the later stage of epidemic prevention.

This study was limited by the qualitative IgG tests and short follow-up period. Further study should focus on the time-dependent change of the antibody level and the identification of those who are still at risk of re-infection in recovered patients.

Acknowledgements

Not applicable.

Authors' contributions

Y.S. and D.C. came up with the question, and J.L. and J.G. were responsible for the data extraction and analysis. Q.X. and G.C. were responsible for writing. The authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

All the data were available from the corresponding author on a reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

None.

Author details

¹Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Ruijin 2nd Road, Shanghai, China.

²Department of Critical Care Medicine, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, No.999 Xiwang Road, Shanghai, China.

³Department of Critical Care Medicine, Huazhong University of Science and Technology Union Jiangbei Hospital, 111 Success Avenue, Wuhan, China.

⁴Department of Critical Care Medicine, Zhejiang Hospital, No. 12, Linyin Road, Hangzhou 310000, Zhejiang, People's Republic of China.

Received: 7 June 2020 Accepted: 1 July 2020

Published online: 20 July 2020

References

1. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR test results in patients recovered from COVID-19. *JAMA*. 2020;323(15):1502–3.
2. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect*. 2020;9(1):386–9.
3. Qin W, Sun G, Zhang Y, et al. Patients with COVID-19 testing positive for nucleic acids of SARS-CoV2 in re-examination after discharge from hospital: an analysis of three cases. *Chinese J Virol*. 2020;10(2):1–4.
4. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, Song S, Ma Z, Mo P, Zhang Y. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis*. 2020;221(11):1762–9.
5. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy*. 2020;75(7):1564–81.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

